Management Team
Lynn brings significant sales and marketing experience, including as president and a founding partner of a startup in one-to-one marketing and as a senior vice president at Digitas, managing interactive marketing relationships and strategy development across a range of industries. Lynn spent a decade at the Boston Consulting Group as a member of the Health Care practice focusing on payors and hospitals. She had previously focused on the securities industry and how to use information for strategic advantage. Her work was detailed in her article, “Stay Small or Get Huge: Lessons from the Securities Industry,” published in the Harvard Business Review. She received her M.B.A from Harvard Business School, awarded with distinction and her B.A. from Radcliffe College, with magna cum laude honors.
Dr. Segal did his undergraduate work at Harvard and his MD and PhD at Columbia, where his thesis project outlined rules for the types of chemical synapses that will form in a nervous system. After his residency in pediatric neurology at Columbia, he moved to Harvard Medical School, where he joined the faculty and developed the microisland system for studying neural networks with as few as one or two brain neurons. Using this system, he developed a reductionist model of epilepsy, work that won him national and international young investigator awards, and set the stage for later work on the molecular mechanism of attention deficit disorder. In the 1980s he started teaching at Harvard about the relationship between computer and biological neural networks, as well as publishing about the relationship between artificial intelligence and biological neural networks. He patterned the SimulConsult software after the way that experienced clinicians actually think about diagnosis. He is on the Electronic Communication Committee of the Child Neurology Society and has been on the Scientific Program Committee of the American Medical Informatics Association. Click here for a list of publications.
Rick has been building early-stage companies and developing practical, break-through strategies for more than twenty-five years. He has been CEO or COO of eleven companies; most recently Thermalin Diabetes, LLC (CEO, biotech) and HeartLander Surgical, Inc. (CEO, medical device). Rick has also led companies in consumer products manufacturing, knowledge management, new media, entertainment industry technology, manufacturing software, healthcare information and services, healthcare market research, diagnostic reference laboratory services, and cancer immunotherapeutics. He has raised or helped raise more than $35M in private and non-dilutive capital. As Managing Director of his consulting firm, Venzyme Catalyst, LLC, he has helped launch and finance life science organizations around important new technologies in complex markets. Rick received a JD-MBA from Harvard Law and Business Schools in 1984 and is a graduate of Harvard College.
Mark Zbikowski is the CTO at SimulConsult. He is a former Microsoft Architect. He started working at Microsoft only a few years after its inception, leading efforts in MS-DOS, OS/2, Cairo and Windows NT. In 2006, he was honored for 25 years of service with Microsoft, the first employee to reach this milestone other than Bill Gates and Steve Ballmer. Mark retired from Microsoft in June 2006, has served as the CTO at startups and is currently a technical adviser to several companies. He was the designer of the DOS executable file format, used in MS-DOS executable files, and his initials are the first 2 bytes of those files.
Board of Directors
David is a retired Senior Partner at The Boston Consulting Group. He founded BCG’s health care practice and has led BCG’s Boston office, among many other roles for the firm. His work has focused on strategies for integrating health care, and especially on the role of health care technology in driving this. He has been deeply associated with the development of disease management and wellness and has published several articles on those topics. David received a JD from Harvard Law School, an MBA from Harvard Business School and an MA from the University of St Andrews.
Rick has been building early-stage companies and developing practical, break-through strategies for more than twenty-five years. He has been CEO or COO of eleven companies; most recently Thermalin Diabetes, LLC (CEO, biotech) and HeartLander Surgical, Inc. (CEO, medical device). Rick has also led companies in consumer products manufacturing, knowledge management, new media, entertainment industry technology, manufacturing software, healthcare information and services, healthcare market research, diagnostic reference laboratory services, and cancer immunotherapeutics. He has raised or helped raise more than $35M in private and non-dilutive capital. As Managing Director of his consulting firm, Venzyme Catalyst, LLC, he has helped launch and finance life science organizations around important new technologies in complex markets. Rick received a JD-MBA from Harvard Law and Business Schools in 1984 and is a graduate of Harvard College.
Lynn brings significant sales and marketing experience, including as president and a founding partner of a startup in one-to-one marketing and as a senior vice president at Digitas, managing interactive marketing relationships and strategy development across a range of industries. Lynn spent a decade at the Boston Consulting Group as a member of the Health Care practice focusing on payors and hospitals. She had previously focused on the securities industry and how to use information for strategic advantage. Her work was detailed in her article, “Stay Small or Get Huge: Lessons from the Securities Industry,” published in the Harvard Business Review. She received her M.B.A from Harvard Business School, awarded with distinction and her B.A. from Radcliffe College, with magna cum laude honors.
Dr. Segal did his undergraduate work at Harvard and his MD and PhD at Columbia, where his thesis project outlined rules for the types of chemical synapses that will form in a nervous system. After his residency in pediatric neurology at Columbia, he moved to Harvard Medical School, where he joined the faculty and developed the microisland system for studying small numbers of brain neurons in culture. Using this system, he developed a simplified model of epilepsy, work that won him national and international young investigator awards, and set the stage for later work on the molecular mechanism of attention deficit disorder. Dr. Segal has a long history of interest in artificial intelligence and neural networks, and patterned the SimulConsult software after the way that experienced clinicians actually think about diagnosis. He is on the Electronic Communication Committee of the Child Neurology Society is one of the medical advisers of the Periodic Paralysis Association, and has been on the Scientific Program Committee of the American Medical Informatics Association. Click here for a list of publications.
Former President & CEO of Atrius Health with over 6,800 clinicians. Dr. Strongwater is an adult Rheumatologist. Prior to joining Atrius, Dr. Strongwater was the Chief Transformation Officer at Geisinger Health System. He previously had been the CEO of Stony Brook University Hospital. Dr. Strongwater sits on the Mass Digital Health Council and is a board member of Atalan. He received a BS from the University of Rochester and his MD from the Upstate Medical School.
Advisory Board
Business
Sandra L. Fenwick
Sandra L. Fenwick was the Chief Executive Officer of Boston Children’s Hospital, where she led a team of 20,000 people. Ms. Fenwick is a member of the Board of Directors of the Children’s Hospital Association and chairs its Public Policy Committee. She serves on the Board of Directors of CRICO, Livongo Health, Harvard’s Wyss Institute for Biologically-inspired Engineering, Jobs for Massachusetts, the Massachusetts Digital Health Council, and Boston Children’s Hospital. She is also a member of the Massachusetts Women’s Forum and Women Corporate Directors/Boston. Ms. Fenwick holds a Bachelor’s degree from Simmons College with distinction and a Master’s in Public Health in Health Services Administration from the University of Texas School of Public Health.
David Williams
David Williams is co-founder of MedPharma Partners LLC, a strategy consulting firm in technology-enabled health care services, pharmaceuticals, biotech, and medical devices and author of the Health Business Blog. He is also chairman of the medical risk management company Advanced Practice Strategies, a board member of ECG biomarker company iCardiac Technologies, and chairman of Hearts & Noses Hospital Clown Troupe. He was formerly a consultant with the Boston Consulting Group and LEK. David received his MBA from Harvard Business School and his BA from Wesleyan University.
Clinical
Abraham Fuks MD CM
Dr. Fuks is Professor in the Departments of Medicine, Pathology and Oncology at McGill University and is the immediate past Dean of the Faculty of Medicine. Dr. Fuks is a graduate of the Faculty of Medicine at McGill University, where he obtained his MD in 1970. Following training in internal medicine and clinical immunology in the McGill teaching hospital network, he did three-years of postdoctoral training at Harvard University in the fields of immunogenetics and biochemistry. His current scholarly interest is in the language of medicine and its metaphoric structure and the narratives of the doctor-patient relationship. He teaches medical students at various points in their training and is in the process of using SimulConsult to teach medical reasoning.
Steven G. Pavlakis MD
Dr. Pavlakis is Professor of Neurology and Pediatrics at Mount Sinai School of Medicine and the Director of Developmental Medicine and Child Neurology at Maimonides Infants and Children’s Hospital, where he is Chief Scientific Officer for Maimonides Medical Center Office of Health Sciences and Research and the Maimonides Research Foundation. His research interests include mitochondrial diseases, stroke, sickle cell disease, as well as pediatric hypertension and its affects on vasculature. His received his Bachelor of Science in biology and an MD from Brown University, and trained at Columbia-Presbyterian Medical Center.
Technology
Henry Feldman, MD
Henry Feldman, MD is Deputy Chief Medical Officer – Technology at IBM Watson. He is also an Assistant Professor of Medicine at Harvard Medical School and hospitalist at the Beth Israel Deaconess Medical Center in the Division of General Internal Medicine, where he was also the Chief Architect of their clinical informatics group for a decade before joining IBM. Prior to becoming a physician he was in the computer industry for almost 10 years, serving with such companies as Microsoft, two subsidiaries of Allen-Bradley, and The Boston Consulting Group. For the 2 years prior to coming to Harvard, he served in the section of Medical Informatics at NYU School of Medicine, and created the web based virtual patient modules as part of the CDC Psychosocial Aspects of Bioterrorism grant as well as computerizing outpatient clinic scheduling.